Theo-24(Theophylline Anhydrous)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$3.2M
Medicare cost, 2024
$3.2M
Medicare cost, 2024
Medicare drug plans spent $3.2 million on Theo-24 (theophylline anhydrous) in 2024, for 10,314 prescriptions and refills filled by 2,809 patients. California accounts for the most spending ($340,854, 11% of the total).
Medicare cost, 2024
$3.2M
-8.6% from 2023
Prescriptions
10K
$310.23 per claim
Patients
2,809
2,828 prescribers
Total spending, 2024
$3.2M
$1,138.69 per patient
Questions and answers
How much does Medicare spend on Theo-24?
Medicare prescription drug plans paid $3.2M for Theo-24 in 2024, for 10,314 prescriptions and refills to 2,809 patients (down 8.6% from 2023). The average cost per claim was $310.23.
Which state spends the most on Theo-24?
California had the highest Medicare cost for Theo-24 in 2024: $341K for 992 claims, followed by Florida ($241K).
Who prescribes Theo-24 the most?
Robert G Shellman, pulmonary disease in Shelbyville, IN, had the highest Medicare cost for Theo-24 in 2024: 51 claims costing $14K.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Theo-24 was $3.2M in 2024, after a high of $7.6M in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Theo-24, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Robert G Shellman Shelbyville, IN | Pulmonary Disease | 51 | Under 11 | $14K |
| Ammar M Shaheen Merrillville, IN | Pulmonary Disease | 54 | 22 | $14K |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 26 | Under 11 | $11K |
| Moin A Ranginwala Springfield, OH | Pulmonary Disease | 20 | Under 11 | $9,831 |
| Eric Shore Hartford, CT | Pulmonary Disease | 14 | Under 11 | $8,529 |
| M. Firas Joudeh Tempe, AZ | Critical Care (Intensivists) | 24 | Under 11 | $8,372 |
| Mustafa Rahim Beckley, WV | Internal Medicine | 60 | Under 11 | $7,926 |
| Jesus Vazquez Arcadia, CA | Clinical Cardiac Electrophysiology | 18 | Under 11 | $7,866 |
| Muhammad A Ahmed Russellville, KY | Pulmonary Disease | 14 | Under 11 | $7,393 |
| Richard L Coven Amityville, NY | Internal Medicine | 25 | Under 11 | $7,358 |
| Aijaz A Yazdani Elizabethtown, KY | Pulmonary Disease | 22 | Under 11 | $7,202 |
| Muhammad I Ali Johnson City, NY | Pulmonary Disease | 17 | Under 11 | $7,153 |
| Udaya Shreesha Weston, WI | Pulmonary Disease | 36 | Under 11 | $6,846 |
| Cecily Y Verhoven Danville, KY | Nurse Practitioner | 13 | Under 11 | $6,683 |
| Humberto J Hernandez Hialeah, FL | Internal Medicine | 18 | Under 11 | $6,513 |
| Carroll A Pinner III Peak, SC | General Practice | 12 | Under 11 | $6,358 |
| Richard F Kucera Greensburg, PA | Pulmonary Disease | 43 | Under 11 | $6,327 |
| Alayna C Pine Minneapolis, MN | Nurse Practitioner | 11 | Under 11 | $6,261 |
| Owen M Meyers Monroe, LA | General Practice | 12 | Under 11 | $6,202 |
| Berhanemeskel Nesketa Owensboro, KY | Pulmonary Disease | 11 | Under 11 | $6,186 |
| Wael Tello Lubbock, TX | Pulmonary Disease | 24 | Under 11 | $6,104 |
| Mario Espinosa Garcia Bayamon, PR | Pulmonary Disease | 11 | Under 11 | $6,065 |
| Ronald A Reiss Hillsborough, NJ | Family Practice | 23 | Under 11 | $5,683 |
| Shahid Bashir Sullivan, IN | Pulmonary Disease | 20 | Under 11 | $5,640 |
| Ayla Gordon Marietta, OH | Pulmonary Disease | 13 | Under 11 | $5,473 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 5,421 | 24,820 | 5,444 | $7.1M |
| 2023 | 3,904 | 12,454 | 3,977 | $3.5M |
| 2024 | 2,828 | 10,314 | 2,809 | $3.2M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Auxilium/Endo P | 10,315 | $3.2M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 4
- RxNorm concept IDs
- 198264, 313272, 313310, 701712, 844590
- Application numbers
- ANDA081034, ANDA087942, ANDA087943, ANDA087944
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 12,470 side-effect reports named theophylline anhydrous, the active ingredient of Theo-24 (reports from 1995 on). 10,214 of them (81.9%) were serious, 1,794 named a death and 5,406 named a hospital stay. The reactions named most often were dyspnoea, asthma and pneumonia. 2,993 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
12,470
636 in 2025 (-2.0% from 2024)
Serious
81.9%
10,214 reports
Deaths named
1,794
14.4% of reports
Hospital stays
5,406
43.4% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
Since 2002. 2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Theo-24?
12,470 reports from 1995 through September 2026 named theophylline anhydrous, the active ingredient of Theo-24. 10,214 of them (81.9%) were serious, 1,794 named a death and 5,406 named a hospital stay.
What are the most reported side effects of Theo-24?
2,502 reports named dyspnoea, the reaction named most often, followed by asthma (2,155) and pneumonia (1,517). In the last 5 years the reaction named most often was asthma (1,107 reports). A report can name several reactions.
How many side-effect reports named Theo-24 in 2025?
636 reports were received in 2025 (-2.0% from 2024). 2026 so far: 459 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Theo-24 caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Theo-24 caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with theophylline anhydrous: Theophylline Er, Elixophyllin
- Drug approvals (4 approvals on file for theophylline anhydrous) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (theophylline anhydrous) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.